CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Aglaia Therapeutics to Use New Funding for Oncology Targeted Therapies

Life Sciences Review Life Sciences Review | Monday, October 25, 2021
Tweet

Aglaia Therapeutics Raises $4.7 M to develop oncology therapies for cancer patients who have become resistant to current targeted therapies.


FREMONT, CA: The primary goal of cancer treatment is to cure the disease, but also focusing on life extension and pain alleviation in cases when cure is not possible owing to advanced disease. Aglaia Therapeutics has raised $4.7 million in seed funding to create the preclinical development program required to identify the first candidate for clinical trials. The funding round was led by Advent France Biotechnology (AFB), with participation from Crdit Mutuel Innovation and Pierre Fabre. Alejo Chorny, a current AFB operating partner who has been named chief operating officer (COO) of Aglaia Tx, was also a co-founder. The company was founded in collaboration with the Institut Curie and Gustave Roussy, two leading European cancer institutes.


Aglaia Tx's mission is to develop promising novel oncology medicines with the goal of producing best-in-class and first-in-class pharmaceuticals that can restore sensitivity to current targeted therapies in cancer patients who have become resistant to them. The business developed a small chemical pipeline in oncology that targets the start of mRNA translation.


“Our goal is to dramatically improve the standard of care in cancer patients; by restoring sensitivity and avoiding resistance to current targeted therapies. 


We have assembled a strong team of drug developers, scientists and investors,” states Alejo Chorny, COO of Aglaia Therapeutics. “With this seed investment, Aglaia Therapeutics is extremely well-positioned to advance its preclinical programs in the coming years and select its first innovative program.”


While targeted therapies have definitely improved cancer patient outcomes, their overall efficacy decreases with time, and patients develop resistance to these treatments quickly. Furthermore, even when cancer cells respond entirely to treatment, small populations of cancer cells typically survive, leading to cancer relapse, which remains one of the most challenging impediments to effective treatment.


“Aglaia Tx is a good example of our entrepreneur-investor approach and we firmly believe that its work opens up the possibility of tackling relapses, one of the main unmet medical needs in cancer treatment today,” adds Matthieu Coutet, Managing Partner at AFB. “We are thrilled to bring together two leading European cancer institutes, Gustave Roussy and Institut Curie; to collaborate on this unique startup creation aimed at overcoming resistance in oncology targeted therapies.”


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/aglaia-therapeutics-to-use-new-funding-for-oncology-targeted-therapies-nwid-599.html